Lemborexant

Lemborexant is an orally taken hypnotic medication belonging to the class known as dual orexin receptor antagonists, marketed under the brand name Dayvigo and developed by the pharmaceutical company Eisai ^[1][2]. It was approved by the United States Food and Drug Administration in 2019 for the treatment of insomnia in adults, covering difficulty falling asleep as well as difficulty staying asleep ^[1][2].

The compound belongs to a family of newer sleep drugs that target the orexin system rather than the pathways used by benzodiazepines and the so-called Z-drugs ^[2]. In a phase 3 randomized trial in older adults with insomnia, lemborexant improved objective measures of both sleep onset and sleep maintenance compared with placebo, and it also outperformed an extended-release form of the Z-drug zolpidem on some sleep-maintenance measures, while being generally well tolerated ^[1]. A later systematic review and network meta-analysis of orexin antagonists concluded that these drugs are more effective than placebo for insomnia and that the response tends to be dose-related, with lemborexant among the better-performing agents ^[2][3].

The most common side effects are daytime sleepiness or fatigue, headache, and abnormal or vivid dreams; because orexin antagonists promote sleep, next-day drowsiness is the main practical concern ^[1][3]. Lemborexant is cleared mainly by the liver enzyme CYP3A4, so other drugs that affect that enzyme can change its levels ^[2]. In the United States it is a Schedule IV controlled substance, reflecting a low but recognized potential for misuse, and it is approved in several countries including Canada, Australia, and Japan, though not by the European Medicines Agency ^[2].

The most common effects are next-morning sleepiness and headache; it can impair next-day driving and alertness, especially at higher doses. Sleep paralysis, hallucinations on falling asleep or waking, and complex sleep behaviors are less common. It is a controlled substance, should not be combined with alcohol or other CNS depressants, and is prescription-only.

Lemborexant is metabolized primarily by CYP3A4, so co-administration with strong or moderate CYP3A inhibitors (for example itraconazole, ketoconazole, clarithromycin, fluconazole) raises its plasma exposure and the FDA label advises against concomitant use with strong inhibitors and dose limitation with moderate ones. Strong or moderate CYP3A inducers (rifampin, carbamazepine, St. John's wort) reduce lemborexant exposure and can blunt efficacy. Combined use with alcohol or other CNS depressants (benzodiazepines, opioids, other sedative-hypnotics) produces additive psychomotor and respiratory depression, and next-day driving impairment is documented. It also modestly raises exposure of CYP3A and CYP2B6 substrates in some studies, so sensitive substrates warrant monitoring. This is research information, not medical advice.

Checking a whole stack? Run it through interactions + stacks.

Lemborexant was discovered and developed by the Japanese pharmaceutical company Eisai as part of a new generation of sleep medicines built around the orexin system, the brain's principal wake-promoting signal. It belongs to the dual orexin receptor antagonist class, blocking both orexin-1 and orexin-2 receptors, and its clinical program centered on two large phase 3 trials known as SUNRISE 1 and SUNRISE 2. SUNRISE 1 compared it against both placebo and the widely used hypnotic zolpidem in older adults, while SUNRISE 2 assessed long-term efficacy and safety over twelve months. On the strength of these studies it received US Food and Drug Administration approval in December 2019 under the brand name Dayvigo for the treatment of insomnia in adults. Because of its central nervous system effects it is classified as a controlled substance.

Lemborexant is regarded as a modern, well studied option for insomnia that improves both falling asleep and staying asleep. Its class-defining appeal is that it turns down an arousal signal rather than broadly sedating the brain like benzodiazepines and Z-drugs, an approach thought to yield more natural-feeling sleep. The evidence behind it is robust; in the SUNRISE trials it significantly outperformed placebo on objective and patient-reported sleep measures, and on some overnight measures it exceeded zolpidem, all while being generally well tolerated. Reassuringly, serious adverse events in these studies were rare. The most common trade-off is next-morning drowsiness in some users, a consequence of lingering orexin blockade. On balance, lemborexant is considered a strong, evidence-backed choice within the newer orexin-antagonist category.